Xenon Pharmaceuticals Inc.XENEEarnings & Financial Report
Nasdaq · Health Care · Pharmaceutical Preparations
Xenon Pharmaceuticals Inc. is a clinical-stage biopharmaceutical firm focused on developing innovative therapies for neurological and rare disorders. Its core pipeline targets epilepsy, migraine and other central nervous system diseases, serving patients mainly across North America and Europe via partnerships to advance clinical candidates.
Top Holders
| Holder | % Owned | Shares | Change | As of |
|---|---|---|---|---|
| FMR LLC | 9.06% | 6.9M | ▲ +1.51pp | 2024-11-12 |
| Avoro Capital Advisors LLC | 7.70% | 5.7M | — | 2024-02-14 |
| DRIEHAUS CAPITAL MANAGEMENT LLC | 5.88% | 4.3M | — | 2024-02-14 |
| Wellington Management Group LLP | 5.56% | 4.2M | — | 2024-02-08 |
Insider Transactions
Net 90d: −$17.85M · buys $0 / sells $17.85MRange:
Action:
Role:
| Insider | Role | Action | ||||
|---|---|---|---|---|---|---|
| 2026-03-13 | MORTIMER IAN | PRESIDENT & CEO | Sell (open market) | 7.3K | $55.23 | $403.6K |
| 2026-03-13 | KENNEY CHRISTOPHER JOHN | Chief Medical Officer | Sell (open market) | 1.4K | $55.23 | $77.9K |
| 2026-03-13 | DiFabio Andrea | Chief Legal Officer | Sell (open market) | 1.3K | $55.23 | $74.1K |
| 2026-03-12 | MORTIMER IAN | PRESIDENT & CEO | Option exercise | 12.5K | — | — |
| 2026-03-12 | KENNEY CHRISTOPHER JOHN | Chief Medical Officer | Option exercise | 3.8K | — | — |
| 2026-03-12 | DiFabio Andrea | Chief Legal Officer | Option exercise | 3.8K | — | — |
| 2026-03-10 | DiFabio Andrea | Chief Legal Officer | Sell (open market) | 2.6K | $60.11 | $156.7K |
| 2026-03-10 | KENNEY CHRISTOPHER JOHN | Chief Medical Officer | Sell (open market) | 2.8K | $60.11 | $166.6K |
| 2026-03-10 | MORTIMER IAN | PRESIDENT & CEO | Sell (open market) | 11.3K | $60.11 | $677.4K |
| 2026-03-09 | DiFabio Andrea | Chief Legal Officer | Option exercise | 7.5K | — | — |
1–10 of 25
Page 1 / 3